Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2011
Erlotinib-induced rash spares previously irradiated skin.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lips Irene M, Koster Mariska E Y, Houwing Ronald H, Vonk Ernest J A
Аннотация
BACKGROUND: Erlotinib is an epidermal growth factor receptor inhibitor prescribed to patients with locally advanced or metastasized non-small cell lung carcinoma after failure of at least one earlier chemotherapy treatment. Approximately 75% of the patients treated with erlotinib develop acneiform skin rashes.
CASE REPORT: A patient treated with erlotinib 3 months after finishing concomitant treatment with chemotherapy and radiotherapy for non-small cell lung cancer is presented. Unexpectedly, the part of the skin that had been included in his previously radiotherapy field was completely spared from the erlotinib-induced acneiform skin rash.
CONCLUSION: The exact mechanism of erlotinib-induced rash sparing in previously irradiated skin is unclear. The underlying mechanism of this phenomenon needs to be explored further, because the number of patients being treated with a combination of both therapeutic modalities is increasing. The therapeutic effect of erlotinib in the area of the previously irradiated lesion should be assessed.
CASE REPORT: A patient treated with erlotinib 3 months after finishing concomitant treatment with chemotherapy and radiotherapy for non-small cell lung cancer is presented. Unexpectedly, the part of the skin that had been included in his previously radiotherapy field was completely spared from the erlotinib-induced acneiform skin rash.
CONCLUSION: The exact mechanism of erlotinib-induced rash sparing in previously irradiated skin is unclear. The underlying mechanism of this phenomenon needs to be explored further, because the number of patients being treated with a combination of both therapeutic modalities is increasing. The therapeutic effect of erlotinib in the area of the previously irradiated lesion should be assessed.
Предметные рубрики MeSH
Carcinoma, Non-Small-Cell LungCombined Modality TherapyDisease ProgressionDose Fractionation, RadiationDrug EruptionsErlotinib HydrochlorideFatal OutcomeHumansImage Processing, Computer-AssistedLung NeoplasmsMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPleural NeoplasmsProtein Kinase InhibitorsQuinazolinesRadiodermatitisRadiotherapy, AdjuvantTomography, X-Ray Computed